Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARNAB BASU

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669734083
CMS profile
2785784
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$133,712.06

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $110,644.10 90
Astellas Pharma US Inc $10,937.38 6
PFIZER INC. $6,975.64 6
EMD Serono, Inc. $2,375.00 1
Exelixis Inc. $1,936.78 2
AstraZeneca Pharmaceuticals LP $400.00 1
Aveo Pharmaceuticals, Inc. $338.82 3
Genentech USA, Inc. $46.49 1
Tempus AI, Inc $30.90 2
E.R. Squibb & Sons, L.L.C. $26.95 1

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARNAB BASU

NPI 1669734083 · CMS profile ID 2785784

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669734083?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARNAB BASU, NPI 1669734083, CMS profile ID 2785784. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669734083?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ARNAB BASU, NPI 1669734083, CMS profile ID 2785784. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669734083?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ARNAB BASU, NPI 1669734083, CMS profile ID 2785784, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1669734083?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $133,712.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $106.3701/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731339 CMS
Eisai Inc. $1,962.5001/23/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731345 CMS
Eisai Inc. $140.3001/23/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155793950 CMS
Eisai Inc. $454.9101/23/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155794438 CMS
Eisai Inc. $16.0101/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731351 CMS
Eisai Inc. $125.0001/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731311 CMS
Eisai Inc. $335.0001/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731317 CMS
Eisai Inc. $4,710.0001/08/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731319 CMS
Eisai Inc. $1,962.5001/08/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731343 CMS
Eisai Inc. $183.4501/08/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155793750 CMS
Eisai Inc. $183.4501/08/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155794226 CMS
E.R. Squibb & Sons, L.L.C. $26.9501/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101552419 CMS
Eisai Inc. $2,355.0001/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110731403 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,433.80 15
PY2020 $1,939.45 14
PY2021 $8,928.19 11
PY2022 $91,130.44 109
PY2023 $133,142.47 134
PY2024 $133,712.06 113
PY2025 $68,264.34 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $846,168.81 89
PY2024 Principal investigator $1,366,484.71 151
PY2023 Principal investigator $1,024,573.93 248
PY2022 Recipient $2,454.89 9
PY2022 Principal investigator $562,727.77 66
PY2021 Principal investigator $308,560.60 8
PY2020 Principal investigator $40,374.45 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $46,207.89 12/18/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726468
Principal investigator 2 Merck Sharp & Dohme LLC $6,368.40 11/05/2025 Non-covered Recipient Entity
University of Alabama - Birmingham
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232930928
Principal investigator 1 PFIZER INC. $46,207.89 09/22/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726636
Principal investigator 1 PFIZER INC. $46,207.89 09/19/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726920
Principal investigator 1 PFIZER INC. $46,207.89 07/02/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727175
Principal investigator 1 MEDIVATION LLC. $321.30 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742405
Principal investigator 1 MEDIVATION LLC. $1,294.02 07/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756913
Principal investigator 1 PFIZER INC. $46,207.89 07/01/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727023
Principal investigator 1 Aveo Pharmaceuticals, Inc. $159.71 06/16/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913389
Principal investigator 1 Aveo Pharmaceuticals, Inc. $498.00 06/02/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913387
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790335
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790694
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790697
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791070
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791074
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791383
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791385
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791602
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792537
Principal investigator 1 MEDIVATION LLC. $1,294.02 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792541
Principal investigator 1 MEDIVATION LLC. $321.30 06/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793152
Principal investigator 2 Merck Sharp & Dohme LLC $5,937.20 06/02/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232929963
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,368.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913379
Principal investigator 1 Aveo Pharmaceuticals, Inc. $390.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913381
Principal investigator 1 Aveo Pharmaceuticals, Inc. $367.90 05/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913383
Principal investigator 1 Aveo Pharmaceuticals, Inc. $130.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913385
Principal investigator 1 Aveo Pharmaceuticals, Inc. $156.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913391
Principal investigator 1 Genentech, Inc. $12,226.00 05/16/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211561011
Principal investigator 1 Genentech, Inc. $11,691.00 05/15/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560975
Principal investigator 1 Genentech, Inc. $12,211.00 05/15/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560979
Principal investigator 1 AstraZeneca Pharmaceuticals LP $57,900.54 05/07/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1185555866
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,265.12 04/28/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913377
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 04/28/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913403
Principal investigator 1 Genentech, Inc. $19,869.00 04/25/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211561003
Principal investigator 1 Merck Sharp & Dohme LLC $8,237.00 04/21/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232930926
Principal investigator 1 Genentech, Inc. $17,757.00 04/16/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560987
Principal investigator 1 Aveo Pharmaceuticals, Inc. $262.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913363
Principal investigator 1 Aveo Pharmaceuticals, Inc. $390.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913365
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,368.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913367
Principal investigator 1 Aveo Pharmaceuticals, Inc. $390.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913369
Principal investigator 1 Aveo Pharmaceuticals, Inc. $130.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913371
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,102.10 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913373
Principal investigator 1 Aveo Pharmaceuticals, Inc. $130.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913375
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,102.10 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913393
Principal investigator 1 Aveo Pharmaceuticals, Inc. $156.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913395
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913397
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,368.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913399
Principal investigator 1 Aveo Pharmaceuticals, Inc. $262.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913401
Principal investigator 1 Genentech, Inc. $12,226.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211561007
Principal investigator 1 PFIZER INC. $46,206.12 04/03/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752496
Principal investigator 1 PFIZER INC. $46,206.12 04/02/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753618
Principal investigator 1 PFIZER INC. $46,207.89 04/02/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754611
Principal investigator 1 MEDIVATION LLC. $999.18 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790331
Principal investigator 1 MEDIVATION LLC. $576.45 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790758
Principal investigator 1 MEDIVATION LLC. $321.30 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792533
Principal investigator 1 MEDIVATION LLC. $212.94 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793057
Principal investigator 1 MEDIVATION LLC. $321.30 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793382
Principal investigator 1 MEDIVATION LLC. $576.45 04/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228794046
Principal investigator 1 Aveo Pharmaceuticals, Inc. $166.00 03/10/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913407
Principal investigator 1 MEDIVATION LLC. $321.30 03/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774028
Principal investigator 1 MEDIVATION LLC. $321.30 03/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774115
Principal investigator 1 MEDIVATION LLC. $1,294.02 03/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785074
Principal investigator 1 Aveo Pharmaceuticals, Inc. $155.13 02/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913313
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,897.70 02/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913315
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 02/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913345
Principal investigator 1 Genentech, Inc. $31,755.00 02/20/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560931
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.00 01/29/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913323
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,897.70 01/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913327
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,607.80 01/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913333
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,607.80 01/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913335
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 01/27/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913341
Principal investigator 1 Genentech, Inc. $31,282.00 01/24/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560948
Principal investigator 1 Genentech, Inc. $310.26 01/15/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560935
Principal investigator 1 Genentech, Inc. $32,105.00 01/15/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560937
Principal investigator 1 Genentech, Inc. $155.13 01/15/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560961
Principal investigator 1 Genentech, Inc. $23,674.00 01/13/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC No dispute reported 06/30/2026 1211560956
Principal investigator 1 PFIZER INC. $46,206.12 01/13/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753717
Principal investigator 1 PFIZER INC. $46,206.12 01/12/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753549
Principal investigator 1 PFIZER INC. $46,207.89 01/12/2025 Non-covered Recipient Entity
University of Alabama
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754723
Principal investigator 1 Aveo Pharmaceuticals, Inc. $110.65 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913317
Principal investigator 1 Aveo Pharmaceuticals, Inc. $390.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913319
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913321
Principal investigator 1 Aveo Pharmaceuticals, Inc. $830.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913325
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913329
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,102.10 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913331
Principal investigator 1 Aveo Pharmaceuticals, Inc. $61.10 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913337
Principal investigator 1 Aveo Pharmaceuticals, Inc. $130.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913339
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,368.00 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913343
Principal investigator 1 Aveo Pharmaceuticals, Inc. $155.13 01/08/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199913405